ERAS News and Press, Erasca Inc. From 08/26/21

Erasca (NASDAQ:ERAS): Q2 GAAP EPS of -$1.20 misses by $0.49. Cash and equivalents of $198.7M Press Release For further details see: Erasca Q2 EPS misses by $0.49

Successfully closed $345 million upsized IPO in July 2021 On track to initiate multiple HERKULES Phase 1b/2 trials in 2021 with data readout(s) beginning in 2022 Strengthened executive leadership team with multiple appointments SAN DIEGO, Aug. 26, 2021 (GLOBE...

You can read full article here. For further details see: Wall Street Breakfast: The Week Ahead (Podcast)

SAN DIEGO, July 20, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the closing of its initial pu...

After a slow start to the month, the IPO market revved back to life with 13 IPOs coming to market this past week. SPAC activity picked up, with seven blank check IPOs raising $940 million. New filers continued to flood the IPO pipeline, with fourteen IPOs and nine SPACs submitting...